Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors

Purpose Endostatin is a 20-kd proteolytic fragment of Collagen XVIII that, in preclinical studies, has been shown to have antiangiogenic and antitumor activity. Both preclinical and human phase I studies of recombinant human endostatin (rhEndostatin) suggested activity in neuroendocrine tumors, which are known to be hypervascular. We therefore performed a multicenter phase 11 study of rhEndostatin in patients with carcinoid or pancreatic neuroendocrine tumors. Patients and Methods Forty-two patients with advanced pancreatic endocrine tumors or carcinoid tumors were treated with rhEndostatin administered as a bid subcutaneous injection at a starting dose of 60 mg/m(2)/d. Steady-state trough levels were obtained after 6 weeks of therapy; patients who did not achieve a target therapeutic level of 300 ng/mL underwent dose escalation to 90 mg/m(2)/d. Patients were observed for evidence of toxicity, response, and survival. Results rhEndostatin was associated with minimal toxicity. However, among 40 patients assessable for radiologic response, none experienced partial response to therapy, as defined by WHO criteria. The median steady-state trough level achieved after dose escalation was 331 ng/mL, within the postulated therapeutic range. Conclusion Treatment with rhEndostatin did not result in significant tumor regression in patients with advanced neuroendocrine tumors.